Fishtown Medicine Library
The Engine Room
Stop blaming your age. Fix your engine.

Insulin Resistance at a Normal Weight
A study of 6,247 young adults without diabetes found 4 in 10 had insulin resistance, and close to half were not obese. What that means for your labs.
Read Full Guide
What to Eat, Starting With Breakfast
The 5 food groups you can eat freely, why breakfast should be your biggest meal, and a long list of breakfast options that are more than a small yogurt.

Amycretin: The Amylin/GLP-1 Drug That Comes as a Pill
Amycretin (zenagamtide) is Novo Nordisk's investigational amylin/GLP-1 co-agonist, in both an injection and an oral tablet. What the early-phase trials showed, why the pill matters, how it differs from CagriSema, and the early-stage caveats.

Artificial Sweeteners and Erythritol: What the Evidence Says
Stevia, erythritol, aspartame, allulose - are they safe? A grounded look at the erythritol clotting scare, the aspartame cancer headlines, and what the best evidence shows, from Fishtown Medicine in Philadelphia.

CagriSema Cuts Weight 20 to 23% and Reverses Prediabetes in 88%: What REDEFINE 1-4 Show vs. Tirzepatide
CagriSema pairs the long-acting amylin analog cagrilintide with semaglutide. What REDEFINE 1 (-22.7% weight loss, 88% prediabetes reversal, -10.9 mmHg BP) and head-to-head REDEFINE 4 vs. tirzepatide prove.

Compounded GLP-1 Drugs: Safe? Legal? Where Rules Stand in 2027
Compounded semaglutide and tirzepatide after shortages ended: legal limits since 2025 and 2026, documented safety risks, self-pay prices, and what to ask your doctor.

GLP-1 Drugs and Surgery: Do You Have to Stop Before a Procedure?
Most people can safely continue Ozempic, Wegovy, or Mounjaro before surgery. The 2024 multisociety guidance, why the old week-long hold is out of date, the aspiration risk, and how your care team decides.

Mazdutide: The Oxyntomodulin Drug Approved in China
Mazdutide is a GLP-1/glucagon dual agonist approved in China for weight and diabetes but not the US. What the GLORY-1 trial showed, its effects on uric acid and lipids, how it compares with survodutide and retatrutide, and its status.

The New Weight-Loss Drugs, Compared (2027)
Semaglutide, tirzepatide, orforglipron, retatrutide, and CagriSema compared: mechanism, weight loss, route, and approval status. Which is strongest, which is a pill, which has proven heart benefit, and how to choose.

Orforglipron (Foundayo) Drops Weight 11.2% With Zero Fasting Rules: How It Compares to Oral Semaglutide
FDA-approved in April 2026, Foundayo (orforglipron) is the first non-peptide GLP-1 pill taken with or without food. What ATTAIN-1/2 and head-to-head ACHIEVE-3 vs. oral semaglutide show.

Resmetirom Clears Liver Fat and Regresses MASH Scarring While Lowering ApoB and Lp(a)
Resmetirom (Rezdiffra) is the first FDA-approved liver-directed THR-beta agonist for MASH with F2-F3 fibrosis. Dr. Ash breaks down the Phase 3 MAESTRO-NASH trial, LDL-C reduction (-13.6 to -16.3%), VCTE 8-15 kPa selection, free T4 interpretation, and how it compares with semaglutide.

Retatrutide Cuts Weight 25 to 28% and Clears 86% of Liver Fat: What the Phase 3 TRIUMPH Trials Show
Retatrutide is Eli Lilly's GIP/GLP-1/glucagon triple agonist. What Phase 3 TRIUMPH-1 (-28.3% weight loss) and the Nature Medicine MASLD MRI study (-86% liver fat) prove, plus heart-rate and skin-tingling trade-offs.

Can You Reverse Type 2 Diabetes? What Remission Really Means
Type 2 diabetes can go into remission for many people through substantial weight loss. What the DiRECT trial showed, why doctors say remission instead of cure, the GLP-1 nuance, who is most likely to succeed, and how durable it is.

Semaglutide Cuts Kidney Failure Risk 24% and All-Cause Death 20%: What FLOW Proves for Diabetic Kidney Disease
In the FLOW trial (n=3,533), semaglutide 1.0 mg cut major kidney events by 24% (NNT 20), CV death by 29%, and overall death by 20% with zero initial eGFR dip and Cystatin C confirmation.

Weekly Semaglutide Resolves MASH in 63% of Patients and Regresses Liver Scarring in the ESSENCE Trial
Semaglutide 2.4 mg (Wegovy) earned FDA approval for MASH with F2-F3 fibrosis in August 2025. Dr. Ash explains the Phase 3 ESSENCE trial (62.9% MASH resolution, 36.8% fibrosis improvement), non-biopsy VCTE 8-15 kPa selection, and how it compares with resmetirom and tirzepatide.

Survodutide Pairs GLP-1 Appetite Control With Direct Liver Glucagon Signaling to Clear MASH in Over 60% of Patients
Survodutide is Boehringer Ingelheim's investigational GLP-1/glucagon dual agonist. Dr. Ash breaks down the Phase 2 MASH biopsy trial (47%, 62%, and 43% vs 14% placebo), the 2026 SYNCHRONIZE-MASLD Phase 3 MRI-PDFF trial (84.2% fat reduction), direct liver glucagon signaling, and LIVERAGE Phase 3 trials.

Tirzepatide (Zepbound, Mounjaro): The Dual Incretin Drug
Tirzepatide (Zepbound, Mounjaro) is the dual GIP/GLP-1 drug that beat semaglutide in SURMOUNT-5 (20.2% vs 13.7% weight loss) and earned FDA approval for moderate-to-severe sleep apnea in SURMOUNT-OSA (-51% to -59% AHI).

Acarbose: The Diabetes Drug With a Longevity Signal
Acarbose is an old diabetes drug with a striking mouse-longevity signal. What it does, why longevity researchers watch it, what it is proven to do in people (diabetes prevention rather than heart protection), and its side effects.

Half of Fatty Liver Cases Hide Behind a Normal ALT, and a 10% Weight Loss Resolves MASH in 90% of Patients
Standard lab ALT cutoffs (40 to 55 U/L) miss up to half of fatty liver (MASLD) and MASH cases. Dr. Ash explains healthy ALT ranges, 2-step FIB-4 and FibroScan staging, the 10% weight-loss curve, and FDA-approved MASH drugs.

Finerenone (Kerendia): The Kidney-and-Heart Drug for Diabetes
Finerenone (Kerendia) protects the kidneys and heart in diabetic kidney disease, and now in heart failure. How it works, what the trials showed, the high-potassium caution, and how it fits with SGLT2 inhibitors.

GLP-1 Microdosing: What It Is and Whether It's Worth It
GLP-1 microdosing uses lower-than-standard doses for metabolic and longevity goals instead of maximum weight loss. What the evidence does and doesn't show, who it might fit, and how Fishtown Medicine approaches it in Philadelphia.

Protecting Muscle, Bone, and Gallbladder on a GLP-1
In STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide), 26% to 39% of weight lost was DEXA lean mass. See how exercise and 1.6 to 2.0 g/kg protein protect muscle and hip/spine bone density (S-LiTE and LITOE trials), and how slow flexible titration prevents nausea and gallstones.

GLP-1 Medications vs Bariatric Surgery: How to Choose
GLP-1 medications and bariatric surgery both drive major weight loss and can reverse diabetes, but they differ in size, durability, and trade-offs. How they compare, who fits which, and how Fishtown Medicine helps you decide.

SGLT2 Inhibitors: Heart, Kidney, and the Longevity Question
SGLT2 inhibitors (Jardiance, Farxiga) protect the heart and kidneys, even in people without diabetes, and carry a mouse-longevity signal. The trial evidence, the longevity question, dosing, and the safety points that matter.

Ultra-Processed Food: What It Does to Your Health
Ultra-processed foods make up most of the American diet and are tied to weight gain, diabetes, and heart disease. What counts as ultra-processed, why it overrides your appetite, and how Fishtown Medicine helps you cut it in Philadelphia.

High Uric Acid Without Gout Signals High Insulin and Fructose - Fix the Metabolism Instead of Taking Pills
High serum uric acid tracks fasting insulin (r = -0.69 clearance; +1.18 mg/dL per SD in Mendelian randomization) and liquid fructose ATP depletion, yet 4 major trials (ALL-HEART, PERL, CKD-FIX, FEATHER) show allopurinol does not prevent heart or kidney disease without gout. How we treat the root cause.

The GLP-1 Strategy
Why prescribing the shot is the easy part. Learn how we manage muscle preservation, protein intake, and the exit strategy for sustainable results.

Ozempic vs. Metformin: Which Strategy Wins?
Should you start with the foundation (Metformin) or the heavy hitter (GLP-1)? We break down signaling, metabolic impact, and sustainability.

Weight Loss That Works
A nuance-first approach to GLP-1s. We focus on body composition, not just the number on the scale, with HAES-aligned principles that prioritize health.

Metabolic Flexibility: The Holy Grail
Weight is a lagging indicator. Insulin is a leading indicator. We use fasting insulin, CGMs, and DEXA scans to find and fix metabolic dysfunction.

Metabolism: Getting Your Engine Working Right
A grounded clinical approach to metabolic health and GLP-1s. We focus on biological restoration and body composition, fixing the engine first.

The AIP Diet: Immune Reset
More than just clean eating. Discover how the Autoimmune Protocol (AIP) acts as a diagnostic tool to silence inflammation and identify your specific dietary...

Anxiety & The Gut-Brain Axis
Discover why your anxiety might be a microbial problem. Explore the Psychobiotic revolution and how the Vagus Nerve connects your gut to your brain.

Fasting Protocols: The Goldilocks Zone
Fasting is a tool you can learn to use with care. Here is how to run time-restricted eating, 24-hour fasts, and longer protocols safely while protecting your muscle.

IBS & SIBO: The Root Cause
Bloated after every meal? Up to 60% of IBS cases may be SIBO. Learn how we test, treat, and prevent recurrence.

Leaky Gut: The Science of Permeability
Pseudoscience or real biology? Learn the science of zonulin and how intestinal permeability drives autoimmune disease and chronic inflammation.